Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-PSMA-I&S Biodistribution in Prostate Cancer
NCT04857502Phase 1Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Apr 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of technetium Tc-99m PSMA I&S in prostate cancer (PCa), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Biodistribution of 99mTc-PSMA-I&S in normal and malignant tissues. Started Apr 2021; status: recruiting.
02
Drugs
technetium Tc-99m PSMA I&S
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04857502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857502.